Related references
Note: Only part of the references are listed.A Narrative Review of Studies Comparing Efficacy and Safety of Citalopram with Atypical Antipsychotics for Agitation in Behavioral and Psychological Symptoms of Dementia (BPSD)
Haider Saddam Qasim et al.
PHARMACY (2022)
Factors associated with aggressive behaviour in persons with cognitive impairments using home care services: A retrospective cross-sectional study
Angela Schnelli et al.
NURSING OPEN (2021)
Agitation and Dementia: Prevention and Treatment Strategies in Acute and Chronic Conditions
Claudia Carrarini et al.
FRONTIERS IN NEUROLOGY (2021)
Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials
George T. Grossberg et al.
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY (2020)
Pharmacotherapy of Behavioral and Psychological Symptoms of Dementia: State of the Art and Future Progress
Radoslaw Magierski et al.
FRONTIERS IN PHARMACOLOGY (2020)
Psychosis in Alzheimer's Disease
Clive Ballard et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2020)
Real-World Treatment Patterns and Characteristics Among Patients with Agitation and Dementia in the United States: Findings from a Large, Observational, Retrospective Chart Review
Myrlene Sanon Aigbogun et al.
JOURNAL OF ALZHEIMERS DISEASE (2020)
A Comprehensive Evaluation of Studies on the Adverse Effects of Medications in Australian Aged care Facilities: A Scoping Review
Haider Qasim et al.
PHARMACY (2020)
Efficacy and Safety of Atypical Antipsychotics for Behavioral and Psychological Symptoms of Dementia Among Community Dwelling Adults
Katy E. Trinkley et al.
JOURNAL OF PHARMACY PRACTICE (2020)
Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate
Stephen M. Stahl
CNS SPECTRUMS (2018)
Safety and Efficacy of Anti-dementia Agents in the Extremely Elderly Patients with Dementia
Eun-Ye Lim et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2018)
Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study
Clive Ballard et al.
LANCET NEUROLOGY (2018)
New hope for Alzheimer's dementia as prospects for disease modification fade: symptomatic treatments for agitation and psychosis
Stephen M. Stahl
CNS SPECTRUMS (2018)
Treatment of behavioral and psychological symptoms of dementias with psychopharmaceuticals: a review
Jiri Masopust et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2018)
Trends in Psychotropic Dispensing Among Older Adults with Dementia Living in Long-Term Care Facilities: 2004-2013
Akshya Vasudev et al.
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY (2015)
Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach
Edoardo Aromataris et al.
INTERNATIONAL JOURNAL OF EVIDENCE-BASED HEALTHCARE (2015)
What Is Known About Dementia Care Recipient Violence and Aggression Against Caregivers?
Tracy C. Wharton et al.
JOURNAL OF GERONTOLOGICAL SOCIAL WORK (2014)
A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease
Joel E. Streim et al.
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY (2008)
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: Phase 1 outcomes from the CATIE-AD effectiveness trial
David L. Sultzer et al.
AMERICAN JOURNAL OF PSYCHIATRY (2008)
A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia
Bruce G. Pollock et al.
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY (2007)
Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: A multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses
Jacobo E. Mintzer et al.
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY (2007)
Quetiapine for agitation or psychosis in patients with dementia and parkinsonism
Roger Kurlan et al.
NEUROLOGY (2007)
Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial
H Brodaty et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2005)
Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial
C Ballard et al.
BMJ-BRITISH MEDICAL JOURNAL (2005)
Does behavioral improvement with haloperidol or trazodone treatment depend on psychosis or mood symptoms in patients with dementia?
DL Sultzer et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2001)
Share Paper
